{"title":"In silico evaluation of potential breast cancer receptor antagonists from GC-MS and HPLC identified compounds in Pleurotus ostreatus extracts","link":"http://pubs.rsc.org/en/Content/ArticleLanding/2024/RA/D4RA03832K","date":null,"content":"<div><p><img src=\"/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.svc/ImageService/image/GA?id=D4RA03832K\" /></p></div><div><i><b>RSC Adv.</b></i>, 2024, <b>14</b>,23744-23771<br /><b>DOI</b>: 10.1039/D4RA03832K, Paper</div><div><img alt=\"Open Access\" src=\"http://sod-a.rsc-cdn.org/pubs.rsc-uat.org/content/NewImages/open_access_blue.png\" /> Open Access</div><div><a href=\"http://creativecommons.org/licenses/by-nc/3.0/\" target=\"_blank\"> <img src=\"http://sod-a.rsc-cdn.org/pubs.rsc-uat.org/content/NewImages/CCBY-NC.png\" alt=\"Creative Commons Licence\" /></a>Â  This article is licensed under a <a href=\"http://creativecommons.org/licenses/by-nc/3.0/\" target=\"_blank\">Creative Commons Attribution-NonCommercial 3.0 Unported Licence.</a></div><div>Magdalene Eno Effiong, Mercy Bella-Omunagbe, Israel Sunmola Afolabi, Shalom Nwodo Chinedu<br />Pharmacotherapeutic targets for breast cancer include the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (EGFR).<br />The content of this RSS Feed (c) The Royal Society of Chemistry</div>","author":"","siteTitle":"RSC - RSC Adv. latest articles","siteHash":"da3e282678330308414c63a405ade89dd3738fcce2936ca8a2fe3a6d7e967d99","entryHash":"0c7c9199c5f79c077c1a057b30dbbd9bac80f08037e3e2194e05c8ecf9c0c1d2","category":"Environment"}